trendlines

Investing to improve the human condition.
Food and Health

Steve Rhodes
Chair and CEO

Todd Dollinger
Chair and CEO

Haim Brosh
CFO

December 2022



Legal disclaimer.

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Who we are.

Trendlines is an Israel-based company that trades in Singapore on the SGX (42T) and the USA on the OTCQX (TRNLY).







We invest in agrifood and medtech innovation to improve the human condition.

15
years' investment and company building experience

58*
portfolio companies

20
advanced-stage companies

10
exits

* including venture fund and consolidated companies

9.7X return and 175% IRR on exits

Equity US$94 million (30.06.22)

Leadership.



Todd Dollinger
Chair and CEO

Trendlines' Founder; over 40 years' experience developing innovative products from concept to exit



Steve Rhodes
Chair and CEO

Trendlines' Founder; over 40 years' experience, deep understanding of investing and building companies



Haim Brosh
CFO

20 years' managerial and financial experience in public and private companies



Nitza Kardish PhD
CEO
Trendlines Agrifood

Vast experience in food and agriculture technologies alongside strong business acumen



Barak Singer
CEO,
Trendlines Investments Israel

Extensive investment knowledge & experience + strong managerial and business capabilities



Eric Loh
CEO
Trendlines Medical Singapore

Over 30 years' experience establishing companies and leading their development



Kobby Greenberg
Acting CEO
Trendlines Innovation Labs

Brings a wealth of experience in the medical device industry.

Strategic partnerships for growth.

Consensus Business Group

Chairman Vincent Tchenguiz

- Librae Holdings is Trendlines' largest shareholder (26.5%)
- Trendfood has invested $10M in the Trendlines Agrifood Fund
- Agriline has invested US$30 million in 27 of Trendlines' portfolio companies


B|BRAUN SHARING EXPERTISE

- Investor in Trendlines' IPO, holding 2.9%
- Investor and acquirer of Trendlines' portfolio companies
- Partner with Trendlines Innovation Labs
- Founding partner, Trendlines Medical Singapore

BAYER

- Co-founded venture fund with Trendlines for innovative agrifood investing
- Established four portfolio companies and made follow-on investments in them
- Informed consultation on all things agrifood

A taste of our portfolio.





Some portfolio stats.

58*
portfolio companies

26 agrifood

32 medtech

14
revenue-stage companies

20
companies with strategic partnerships

8
consolidated companies

* including venture fund and consolidated companies

The natural food color revolution.

A broad-spectrum of healthy plant-based colors produced via fermentation technology, using baker's yeast as a biofactory. Phytolon's high-quality and cost-effective pigments offer value for consumers, the environment and food industry.

Achievements:

- Full POC: color production & application in food products
- Commercial agreement with DSM
- Successful pilots with industry leaders including Nestlé
- R&D collaboration agreement with Ginkgo Bioworks

Financial stage:

- Last investment round: US$14.5 million

Phytolon
Natural Food Colors



Plant-based colors produced via cost-effective and sustainable fermentation of yeast

Founded 2018;
23 employees;
Yokne'am Illit, IL

Co-Founders:
Halim Jubran, PhD, CEO;
Tal Zeltzer, PhD, CTO

IP licensed from Weizmann Institute of Science

Funding US$20.1 million

Investors (see below)

tech. dev. stage
agrifood

trendlines Consensus Business Group GINKGO BIOWORKS eit Food DSM CIBUS millennium foodtech ARKIN HOLDINGS

4 more agrifood frontrunners.

26 agrifood portfolio companies

FruitSpec.

Early-stage prediction of crop yields in orchards and vines

- Sales in the United States, South America, Israel and South Africa
- Strategic investors from China and South Africa

METOMOTION

Technology platform for harvesting greenhouse tomatoes

- Partnership with Dutch horticulture technology supplier Ridder
- First commercial sales in 2022
- Received investment from European Innovation Council

AgroScout
Detection Done Right

Artificial intelligence analytics employing drones for user-generated data acquisition for field crop management

- Strategic partners in Israel, North America, Latin America, Europe and Africa. AECI
- Acquired Terravion assets to bolster imagery capabilities.

VIAQUA THERAPEUTICS

Orally-administered disease prevention for shrimp and fish

- Strategic investors:

nutreco NuFrontiers
s2gventures
VisVires New Protein
Thai Union

Needleless neurotoxin delivery for overactive bladder.

Ultrasound catheter used to deliver Xeomin® in the treatment of overactive bladder, a common bladder disorder.

Achievements:

- Successful first in human study
- Strategic collaboration agreement with Merz Therapeutics licensing Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures

Financial stage:

- Last investment round: US$19 million

VENSICA



Ultrasound catheter delivers Xeomin® into the bladder wall painlessly and without needles.

Founded 2014

CEO Avner Geva

IP Filed PCT

Funding Raised US$21 million

Investors (see below)

Lewis Pell – Angel investor

4 more leading medtech companies.

32 medtech portfolio companies

Arcuro Medical

Meniscus repair system

- FDA and CE clearance
- Launched initial commercial sales in U.S., Latin America, U.K.
- Appointed leading surgeons to Scientific Advisory Board

ststent
Short Term Stent Technology

Removable stent following sinus surgery

- Began sales in US
- FDA clearance

liberDi

Digital home dialysis


- FDA clearance in process
- 2nd clinical trial underway
- Raised US$8.1 million

escala medical


Non-surgical, incision-free approach to treat pelvic organ prolapse

- FDA clearance
- 17 patient FIH clinical study with 1 year follow up completed – March 2022


Let’s look at the numbers.



Portfolio value with cumulative exit proceeds.




Book value vs. exit value.



4X is the increase in value of our ten exits, compared to their pre-exit book value.

Investments raised by portfolio companies*



*Including venture fund and consolidated companies

H1 2022: Key Financial Metrics.

	30 June 2022	31 December 2021
Portfolio value:	US$81.0 million	US$83.0 million
Book value:	US$94.2 million	US$102.5 million
NAV per share:	US$0.12	US$0.13
Net (loss)/profit	US$ (11.9 million)	US$4.1 million

Building for future results.



2022 achievements so far.

Selected raises

VENSICA

Completed to US$19 million

Phytolon Natural Food Colors

US$14.5million

SetBone medical

US$1.6 million

Arcuro Medical

US$2.85 million

Strategic collaborations

Phytolon Natural Food Colors

GINKGO BIOWORKS™ THE ORGANISM COMPANY

METOMOTION RIDDER

Regulatory

escala medical

FDA clearance

LIMACA MEDICAL

FDA breakthrough device designation

Clinical & field trials

escala medical

liberDi

METOMOTION

ceretrieve

Leviticus Cardio

PrégnanTech Your Pregnancy. Our Focus.

NeuroQuest



trendlines

Creating & developing companies
to improve the human condition.

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com

December 2022

Steve Rhodes, Chair and CEO
steve@trendlines.com

Todd Dollinger, Chair and CEO
todd@trendlines.com

Haim Brosh, CFO
haim@trendlines.com